Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted): 2020-2022
Historic EPS (Weighted Average and Diluted) for Atea Pharmaceuticals (AVIR) over the last 3 years, with Dec 2022 value amounting to -$0.41.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) fell 131.06% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.40, marking a year-over-year decrease of 204.48%. This contributed to the annual value of -$2 for FY2024, which is 22.70% down from last year.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.41 in Q4 2022, which was down 310.00% from -$0.10 recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $2.62 in Q4 2020 and a low of -$1.74 during Q3 2020.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.34 (2021), whereas its average is $0.04.
- In the last 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) spiked by 105.00% in 2021 and then tumbled by 2,000.00% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at $2.62 in 2020, then crashed by 49.62% to $1.32 in 2021, then crashed by 131.06% to -$0.41 in 2022.
- Its EPS (Weighted Average and Diluted) stands at -$0.41 for Q4 2022, versus -$0.10 for Q3 2022 and -$0.38 for Q2 2022.